Get the Stockscreener App
1.81
0.28%
0.005
After Hours:
1.80
-0.01
-0.55%
Compugen Ltd stock is traded at $1.81, with a volume of 100.49K.
It is up +0.28% in the last 24 hours and down -13.81% over the past month.
See More
Previous Close:
$1.805
Open:
$1.8
24h Volume:
100.49K
Relative Volume:
0.40
Market Cap:
$157.58M
Revenue:
-
Net Income/Loss:
$-18.75M
P/E Ratio:
-4.525
EPS:
-0.4
Net Cash Flow:
$-62.91M
1W Performance:
+2.84%
1M Performance:
-13.81%
6M Performance:
-29.84%
1Y Performance:
+94.62%
1-Day Range:
$1.78
$1.87
1-Week Range:
$1.72
$1.88
52-Week Range:
$0.53
$3.0301
Compugen Ltd Stock (CGEN) Company Profile
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen Ltd. (NASDAQ:CGEN) Sees Large Growth in Short Interest - Defense World
CompoSecure Inc (CMPO) Analyst Thoughts: How High Can It Go? - Stocks Register
Compugen Ltd. (NASDAQ:CGEN) Short Interest Update - Defense World
Compugen Ltd. (NASDAQ:CGEN) Short Interest Update - MarketBeat
Compugen Shareholders Approve All Proposals - TipRanks
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Compugen to Present at Single Cell Genomics 2024 Conference - StockTitan
Compugen Ltd (CGEN)’s Market Momentum: Closing Strong at 1.82, Down -7.61 - The Dwinnex
Compugen Ltd’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Compugen Ltd (CGEN) shows promising results - US Post News
Rothschild Investment LLC Buys Shares of 221,900 Compugen Ltd. (NASDAQ:CGEN) - Defense World
CGENCompugen Ltd Latest Stock News & Market Updates - StockTitan
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues - Simply Wall St
Compugen (NASDAQ:CGEN) Lifted to “Buy” at StockNews.com - Defense World
Compugen (NASDAQ:CGEN) Lifted to Buy at StockNews.com - MarketBeat
Party Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings Forecasts - Yahoo Finance
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript - Seeking Alpha
Compugen (NASDAQ:CGEN) Downgraded by StockNews.com to Hold - Defense World
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven? - Yahoo Finance
Compugen: Q2 Earnings Snapshot - San Antonio Express-News
Compugen: Q2 Earnings Snapshot - The Washington Post
Compugen: Q2 Earnings Snapshot - CT Insider
Compugen Ltd reports results for the quarter ended in JanuaryEarnings Summary - TradingView
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Compugen’s Strategic Milestones Boost Q2 2024 Outlook - TipRanks
Compugen earnings beat by $0.07, revenue topped estimates - Investing.com Australia
Compugen earnings beat by $0.07, revenue topped estimates - Investing.com India
Compugen Reports Second Quarter 2024 Results - StockTitan
Compugen reports Q2 EPS (2c), consensus (7c) - TipRanks
Compugen Ltd. Calls for 2024 Shareholder Meeting - TipRanks
Compugen (CGEN) to Release Quarterly Earnings on Tuesday - Defense World
How to interpret Compugen Ltd (CGEN)’s stock chart patterns - US Post News
Compugen (CGEN) Set to Announce Earnings on Tuesday - MarketBeat
Compugen receives FDA approval for Phase I trial of solid tumour treatment - Clinical Trials Arena
Compugen’s COM503 Advances with FDA Nod and Gilead Deal - TipRanks
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors - Lelezard
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors - StockTitan
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 - StockTitan
Alterity Up on Interim Data From Advance MSA Study - Markets Insider
CGEN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Computational Biology Market will generate new growth - openPR
Computational Biology Market Growth Drivers | Computing Group Inc., Simulation Plus Inc., Compugen Ltd. – Economica - Economica
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag - Zacks Investment Research
The past three years for Compugen (NASDAQ:CGEN) investors has not been profitable - Yahoo Finance
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease - Zacks Investment Research
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug - Zacks Investment Research
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug - Zacks Investment Research
Further weakness as Compugen (NASDAQ:CGEN) drops 15% this week, taking three-year losses to 79% - Simply Wall St
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting - Zacks Investment Research
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):